476 related articles for article (PubMed ID: 34279061)
1. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
2. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
Pina Vegas L; Penso L; Claudepierre P; Sbidian E
JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
[TBL] [Abstract][Full Text] [Related]
3. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.
Pina Vegas L; Le Corvoisier P; Penso L; Paul M; Sbidian E; Claudepierre P
Rheumatology (Oxford); 2022 Apr; 61(4):1589-1599. PubMed ID: 34244706
[TBL] [Abstract][Full Text] [Related]
4. Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Emond B; Ellis LA; Chakravarty SD; Ladouceur M; Lefebvre P
Curr Med Res Opin; 2019 Oct; 35(10):1751-1759. PubMed ID: 31106607
[No Abstract] [Full Text] [Related]
5. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
Penso L; Dray-Spira R; Weill A; Pina Vegas L; Zureik M; Sbidian E
JAMA Dermatol; 2021 Sep; 157(9):1056-1065. PubMed ID: 34287624
[TBL] [Abstract][Full Text] [Related]
6. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors.
Wright S; Alloo A; Strunk A; Garg A
J Am Acad Dermatol; 2020 Aug; 83(2):382-387. PubMed ID: 32289401
[TBL] [Abstract][Full Text] [Related]
7. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
[TBL] [Abstract][Full Text] [Related]
8. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
[TBL] [Abstract][Full Text] [Related]
9. Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.
Jin Y; Lee H; Lee MP; Landon JE; Merola JF; Desai RJ; Kim SC
Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1792-1805. PubMed ID: 33973371
[TBL] [Abstract][Full Text] [Related]
10. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
Vasilakis-Scaramozza C; Persson R; Hagberg KW; Jick S
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1755-1763. PubMed ID: 31981426
[TBL] [Abstract][Full Text] [Related]
11. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Schreiber S; Colombel JF; Feagan BG; Reich K; Deodhar AA; McInnes IB; Porter B; Das Gupta A; Pricop L; Fox T
Ann Rheum Dis; 2019 Apr; 78(4):473-479. PubMed ID: 30674475
[TBL] [Abstract][Full Text] [Related]
12. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
13. Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.
Strunz PP; Englbrecht M; Risser LM; Witte T; Froehlich M; Schmalzing M; Gernert M; Schmieder A; Bartz-Bazzanella P; von der Decken C; Karberg K; Gauler G; Wurth P; Späthling-Mestekemper S; Kuhn C; Vorbrüggen W; Heck J; Welcker M; Kleinert S
Front Immunol; 2024; 15():1395968. PubMed ID: 38846940
[TBL] [Abstract][Full Text] [Related]
14. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting.
Zagni E; Colombo D; Fiocchi M; Perrone V; Sangiorgi D; Andretta M; De Sarro G; Nava E; Degli Esposti L
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):491-497. PubMed ID: 32701033
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
[TBL] [Abstract][Full Text] [Related]
16. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
[TBL] [Abstract][Full Text] [Related]
17. Risk of cancer, tuberculosis and serious infections in patients with ankylosing spondylitis, psoriatic arthritis and psoriasis treated with IL-17 and TNF-α inhibitors: a nationwide nested case-control analysis.
Kim HW; Kim EH; Lee M; Jung I; Ahn SS
Clin Exp Rheumatol; 2023 Jul; 41(7):1491-1499. PubMed ID: 36533975
[TBL] [Abstract][Full Text] [Related]
18. New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study.
Letarouilly JG; Pham T; Pierache A; Acquacalda É; Banneville B; Barbarot S; Baudart P; Bauer É; Claudepierre P; Constantin A; Dernis E; Felten R; Gaudin P; Girard C; Gombert B; Goupille P; Guennoc X; Henry-Desailly I; Jullien D; Karimova E; Lanot S; Le Dantec L; Pascart T; Plastaras L; Sultan N; Truchet X; Varin S; Wendling D; Gaboriau L; Staumont-Sallé D; Peyrin-Biroulet L; Flipo RM
Rheumatology (Oxford); 2022 Jul; 61(7):2848-2855. PubMed ID: 34730790
[TBL] [Abstract][Full Text] [Related]
19. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis.
Burisch J; Eigner W; Schreiber S; Aletaha D; Weninger W; Trauner M; Reinisch W; Narula N
PLoS One; 2020; 15(5):e0233781. PubMed ID: 32459816
[TBL] [Abstract][Full Text] [Related]
20. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]